Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrate for injection
Indication
Treatment of biliary tract cancer
Therapeutic area
Oncology